Evaluasi Penggunaan Terapi Hormonal dan Nonhormonal pada Pasien Rawat Jalan dengan Nyeri Endometriosis di Rumah Sakit Umum Daerah (RSUD) Kota Tangerang Periode 2023–2025

Laila Oktaviana Khoirun Nisa, Andriyani, Yared Yehuda
In: MEDICINUS · 2026 · vol. 39(10) , pp. 16–27 · doi:10.56951/89my9384 · W7215045676
Observational OA: diamond CC0
🔓 Open OA copy Full text JSON View on OpenAlex View at publisher
⚙ AI-generated summary by qwen3.7-flash, 2026-10-04 ⓘ

This retrospective study of 33 outpatient endometriosis patients in Tangerang found that nonhormonal analgesics were the dominant therapy, with medication use demonstrating high appropriateness regarding patient selection, indication, and dosage.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by qwen3.7-flash, 2026-10-04 · read from full text ⓘ

This retrospective study evaluated the appropriateness of hormonal and non-hormonal therapy prescriptions for 33 outpatients with endometriosis-related pain at a regional hospital in Tangerang between 2023 and 2025. The results indicated that non-hormonal treatments, particularly nonsteroidal anti-inflammatory drugs like mefenamic acid, dominated prescribing patterns at 75.76%, while hormonal therapies accounted for only 9.1% to 15.2%. Evaluation metrics showed high adherence to rational drug use principles, with perfect scores for patient selection, indication, and dosage accuracy, and a 93.93% accuracy rate for drug choice. This paper is centrally about endometriosis — specifically the evaluation of pharmacological management strategies for endometriosis-associated pain in an outpatient setting.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

Endometriosis is a chronic gynecological disease characterized by the growth of endometrium-like tissue outside the uterus, leading to dysmenorrhea, infertility, and reduced quality of life. This study aimed to evaluate the usage patterns and appropriateness of hormonal and nonhormonal therapies, specifically regarding the right patient, right drug, right dose, and right indication, among outpatient endometriosis patients at RSUD Kota Tangerang (Tangerang City Regional General Hospital). A retrospective descriptive design was applied in this study, using medical records from January 2023 to October 2025, involving 33 patients. Most patients were aged 35 44 years (51.51%), followed by 25–34 years (27.27%), 45–49 years (15.15%), and 18–24 years (6.06%). Nonhormonal therapy predominated (75.76%), while hormonal and combination therapies accounted for 9.1% and 15.2%, respectively. Analgesics/nonsteroidal anti-inflammatory drugs (NSAIDs) were the most frequently prescribed drug class (66%), followed by progestins (16%) and other medications (18%). Commonly prescribed drugs included mefenamic acid (42%), paracetamol (12%), tramadol (10%), ketorolac (2%), norethisterone (6%), progesterone (10%), ferrous fumarate (6%), folic acid (10%), and calcium carbonate (2%). The evaluation of drug utilization demonstrated 100% appropriateness for patient selection, indication, and dosage, whereas appropriate drug selection reached 93.93%. These findings indicate that nonhormonal therapy remains dominant and the majority of medication use was consistent with the principles of rational drug use.
Full text 9,072 characters · extracted from oa-html · click to expand
Evaluasi Penggunaan Terapi Hormonal dan Nonhormonal pada Pasien Rawat Jalan dengan Nyeri Endometriosis di Rumah Sakit Umum Daerah (RSUD) Kota Tangerang Periode 2023–2025 DOI: https://doi.org/10.56951/89my9384Kata Kunci: endometriosis, terapi, evaluasi penggunaan obatAbstrak Endometriosis merupakan penyakit ginekologi kronis yang ditandai dengan pertumbuhan jaringan mirip endometrium di luar rahim sehingga menyebabkan nyeri haid (dismenorea), infertilitas, dan penurunan kualitas hidup. Penelitian ini bertujuan untuk mengevaluasi pola penggunaan serta ketepatan terapi hormonal dan nonhormonal yang meliputi tepat pasien, tepat obat, tepat dosis, dan tepat indikasi pada pasien endometriosis yang menjalani rawat jalan di RSUD Kota Tangerang. Desain penelitian ini deskriptif retrospektif dengan menggunakan data rekam medis pasien endometriosis periode Januari 2023–Oktober 2025 dengan jumlah sampel sebanyak 33 pasien. Hasil penelitian menunjukkan sebagian besar pasien berada pada kelompok usia 35–44 tahun (51,51%), diikuti kelompok usia 25–34 tahun (27,27%), kelompok usia 45–49 tahun (15,15%), dan kelompok usia 18–24 tahun (6,06%). Penggunaan terapi endometriosis nonhormonal mendominasi sebesar 75,76%, sedangkan terapi hormonal dan terapi kombinasi masing-masing mencakup 9,1% dan 15,2%. Golongan obat yang sering diresepkan adalah analgesik (obat antiinflamasi nonsteroid/OAINS) sebesar 66%, diikuti progestin (16%), dan obat-obatan lainnya (18%). Jenis obat yang digunakan, yaitu asam mefenamat (42%), paracetamol (12%), tramadol (10%), ketorolac (2%), norethisterone (6%), progesterone (10%), ferrous fumarate (6%), asam folat (10%), dan kalsium karbonat (2%). Evaluasi penggunaan obat menunjukkan ketepatan 100% untuk indikator tepat pasien, tepat indikasi, dan tepat dosis, sedangkan indikator tepat obat mencapai 93,93%. Temuan ini menunjukkan bahwa terapi nonhormonal masih mendominasi dan sebagian besar penggunaan obat telah sesuai dengan prinsip penggunaan obat yang rasional. Unduhan Referensi 1. Agarwal SK, Chapron C, Giudice LC, Laufer MR, Leyland N, Missmer SA, et al. Clinical diagnosis of endometriosis: a call to action. Am J Obstet Gynecol. 2019;220(4):354.e1–e12. doi:10.1016/j. ajog.2018.12.039. 2. Rhomadiyah V, Kabuhung EI, Hidayah N, Zulliati. Faktor-faktor yang berhubungan dengan kejadian endometriosis di RSUD Ulin Banjarmasin tahun 2023. J Healthcare Technol Med. 2025;11(1):106–12. 3. Nurjanah SE, Ningrom IC, Purbowati MR, Agatri N, Poernomo MAPD, Marlina D, et al. The impact of endometriosis on the severity of anemia. Indonesian J Health Sci. 2025;5(4):864–70. doi:10.54957/ijhs. v5i4.1597. 4. Halim B, Adiwinata T. Tata laksana terkini untuk endometriosis. Medicinus. 2021;34(3):3–13. doi:10.56951/medicinus.v34i3.77. 5. Ceccaroni M, Bounous VE, Clarizia R, Mautone D, Mabrouk M. Recurrent endometriosis: a battle against an unknown enemy. Eur J Contracept Reprod Health Care. 2019;24(6):464–74. doi:10.1080/13625187.2019.1662391. 6. Zondervan KT, Becker CM, Koga K, Missmer SA, Taylor RN, Viganò P. Endometriosis. Nat Rev Dis Primers. 2018;4(1):9. doi:10.1038/s41572-018-0008-5. 7. Bulun SE. Endometriosis. N Engl J Med. 2009;360(3):268–79. doi:10.1056/NEJMra0804690. 8. Becker CM, Bokor A, Heikinheimo O, Horne A, Jansen F, Kiesel L, et al. ESHRE guideline: endometriosis. Hum Reprod Open. 2022;2022(2):hoac009. doi:10.1093/hropen/hoac009. 9. Lestari YP, Utami AP, Cholila N, Hurin’in NM. Hubungan usia dan paritas dengan stadium pada pasien endometriosis rawat jalan di RSUD Dr. Koesma Tuban. Merapi: Medical Research and Public Health Information Journal. 2024;1(3):12–29. 10. Kapadi R, Elander J. Pain coping, pain acceptance and analgesic use as predictors of health-related quality of life among women with primary dysmenorrhea. Eur J Obstet Gynecol Reprod Biol. 2020;246:40–4. doi:10.1016/j.ejogrb.2019.12.032. 11. Pinto da Costa Viana D, Jacobsen L, Padovesi I, Comin A, Correia EL de S, Fernandes DDM, et al. Tolerability and shared decision-making in the hormonal management of endometriosis-associated pain. Biomedicines. 2025;13(9):2294. doi:10.3390/biomedicines13092294. 12. Weaver J, Chakladar S, Mirchandani K, Liu Z. Surgical and pharmacological treatment patterns in women with endometriosis: a descriptive analysis of insurance claims. J Womens Health (Larchmt). 2022;31(7):1003–11. doi:10.1089/jwh.2021.0060. 13. Brown J, Crawford TJ, Allen C, Hopewell S, Prentice A. Nonsteroidal anti-inflammatory drugs for pain in women with endometriosis. Cochrane Database Syst Rev. 2017;1(1):CD004753. doi:10.1002/14651858. CD004753.pub4. 14. Ali KA, Maity A, Roy SD, Pramanik SD, Das PP, Shaharyar MA. Insight into the mechanism of steroidal and non-steroidal anti-inflammatory drugs. In: How synthetic drugs work. Academic Press; 2023. p.61–94. doi:10.1016/B978-0-323-99855-0.00004-X. 15. Anggraeni KF, Fitriani N, Indriyanti N. Efektivitas asam mefenamat terhadap penurunan nyeri dismenore berdasarkan Numeric Rating Scale. Proc Mul Pharm Conf. 2020;12: 58–61. 16. Crump J, Suker A, White L. Endometriosis: a review of recent evidence and guidelines. Aust J Gen Pract. 2024;53(1-2):11–8. doi:10.31128/AJGP/04-23-6805. 17. Kirsch E, Rahman S, Kerolus K, Hasan R, Kowalska DB, Desai A, et al. Dysmenorrhea, a narrative review of therapeutic options. J Pain Res. 2024;17:2657–66. doi:10.2147/JPR.S459584. 18. Umukoro NN, Jamgbadi SS, Isamade ES. Meperidine-ketorolac combination provides better analgesia than meperidine alone in postoperative patients. Clin Med Res. 2022;20(3):133–40. doi:10.3121/cmr.2022.1628. 19. Pereira A, Herrero-Trujillano M, Vaquero G, Fuentes L, Gonzalez S, Mendiola A, et al. Clinical management of chronic pelvic pain in endometriosis unresponsive to conventional therapy. J Pers Med. 2022;12(1):101. doi:10.3390/jpm12010101. 20. Piriyev E, Schiermeier S, Römer T. Hormonal treatment of endometriosis: a narrative review. Pharmaceuticals (Basel). 2025;18(4):588. doi:10.3390/ph18040588. 21. Wyatt J, Fernando SM, Powell SG, Hill CJ, Arshad I, Probert C, et al. The role of iron in the pathogenesis of endometriosis: a systematic review. Hum Reprod Open. 2023;2023(3):hoad033. doi:10.1093/hropen/ hoad033. 22. Baddam S, Khan KM, Jialal I. Folic Acid Deficiency. [Updated 2025 Jun 25]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026. Available from: https://www.ncbi.nlm.nih.gov/books/NBK535377/ 23. World Health Organization (WHO). Guideline: daily iron supplementation in adult women and adolescent girls. Geneva: World Health Organization; 2016. [cited 2026 Sep 1]. Available from: https://iris.who.int/server/api/core/bitstreams/f354cb76-a596-4275-a489-6d956b4e7dee/content 24. Herdea A, Dragomirescu MC, Ulici A, Nungu CN, Charkaoui A. Controlling the progression of curvature in children and adolescent idiopathic scoliosis following the administration of melatonin, calcium, and vitamin D. Children (Basel). 2022;9(5):758. doi: 10.3390/children9050758. 25. Yeum KJ, Ju S, Choe U. Strategies for preventing bone loss in populations with insufficient calcium and vitamin D intake. Nutr Res Pract. 2025;19(2):155. doi:10.4162/nrp.2025.19.2.155. 26. Gunawan LNA, Wiyono WI, Jayanti M. Evaluasi penggunaan obat rasional pada pasien gagal jantung di Instalasi Rawat Inap RSUP Prof. Dr. R. D. Kandou Manado. J Lentera Farma. 2025;4(1):9–18. doi:10.57207/q6a3e681 27. Finnerup NB. Nonnarcotic methods of pain management. N Engl J Med. 2019;380(25):2440–8. doi:10.1056/NEJMra1807061. 28. Salmasi V, Lii TR, Humphreys K, Reddy V, Mackey SC. A literature review of the impact of exclusion criteria on generalizability of clinical trial findings to patients with chronic pain. Pain Rep. 2022;7(6):e1050. doi:10.1097/PR9.0000000000001050. 29. Kementerian Kesehatan Republik Indonesia. Modul penggunaan obat rasional. Jakarta: Kementerian Kesehatan RI; 2011. [cited 2026 Sep 1]. Available from: https://farmalkes.kemkes.go.id/unduh/modulpenggunaan-obat-rasional/ 30. DiPiro JT, Yee GC, Haines ST, Nolin TD, Ellingrod VL, Posey LM. DiPiro’s pharmacotherapy: a pathophysiologic approach. 12th ed. New York: McGraw Hill; 2023. 31. Song SY, Jung YW, Shin WK, Park M, Lee GW, Jeong S, et al. Endometriosis-related chronic pelvic pain. Biomedicines. 2023;11(10):2868. doi:10.3390/biomedicines11102868. 32. Lanas A, Benito P, Alonso J, Hernández-Cruz B, Barón-Esquivias G, Perez-Aísa Á, et al. Recomendaciones para una prescripción segura de antiinflamatorios no esteroideos: documento de consenso elaborado por expertos nominados por 3 sociedades científicas (SER-SEC-AEG). Gastroenterol Hepatol. 2014;37(3):107–27. doi:10.1016/j.gastrohep.2013.11.014. 33. Dawson TE, Beus J, Orenstein EW, Umontuen U, McNeill D, Kandaswamy S. Reducing therapeutic duplication in inpatient medication orders. Appl Clin Inform. 2023; 14(3):538–43. doi:10.1055/a-2082-4631. Unduhan Terbitan Bagian Diterbitkan Unduhan Lisensi Hak Cipta (c) 2026 Laila Oktaviana Khoirun Nisa, Andriyani, Yared Yehuda Artikel ini berlisensi Creative Commons Attribution-NonCommercial 4.0 International License.

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: oa-html ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (26)

Source provenance

openalex
last seen: 2026-10-13T06:02:51.577429+00:00
License: CC0 · commercial use OK